BIOG B Share Price Performance
SEK 124.50
20.30 (19.48%)
24.5% undervalued intrinsic discount
SEK 165.00
Fair Value
Price SEK 124.50
AnalystConsensusTarget SEK 165.00
Fair ValueSEK 165.00
Share Pricen/a
Narrative Update • Jun 08
BioGaia AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 21 Fair Values set on narratives written by author
BIOG B Community Narratives
AN
Fair Value
·Fair Value SEK 165 24.5% undervalued intrinsic discount
Expanding North American Demand Will Unlock New Health Trends
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
Expanding North American Demand Will Unlock New Health Trends
BioGaia pushes deeper into everyday retail and direct-to-customer sales as more people look for natural, science-backed ways to support gut, mouth, and immune health. The big question is whether today’s heavy spending on new markets, marketing, and research pays off fast enough to reduce its reliance on baby-focused products and avoid a squeeze on profits and cash.Read more
AN
SEK 165
24.5% undervalued intrinsic discount
Fair Value
Revenue
11.17% p.a.
Profit Margin
28.89%
Future PE
31.78x
Price in 2029
SEK 192.59
Trending Discussion
Recently Updated Narratives
AN
BIOG B: Dividend Support And LongevityGuard Stability Will Underpin Future Re Rating
Fair Value: SEK 165 24.5% undervalued intrinsic discount
13 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BioGaia AB (publ) Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 17, 2026
- 3.28
- 72.97%
- 21.49%
- 0%
About BIOG B
- Founded
- 1990
- Employees
- 243
- CEO
- WebsiteView website
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee’s dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.
Recent BIOG B News & Updates
Narrative Update • May 24
